MedTrace Logo

A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM

NCT05918107 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-06-27

No results posted yet for this study

Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with pemetrexed and platinum as first line treatment for MPM.

Conditions

  • MPM

Interventions

DRUG

PM8002

IV infusion

DRUG

Pemetrexed

IV infusion

DRUG

Cisplatin

IV infusion

DRUG

Carboplatin

IV infusion

Sponsors & Collaborators

  • Biotheus Inc.

    lead INDUSTRY

Principal Investigators

  • Ying Cheng · Jilin Provice Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-13
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918107 on ClinicalTrials.gov